NASDAQ:INSM Stockholder Notice: Lawsuit alleges Misleading Statements by Insmed

A stockholder of Insmed Incorporated filed a over alleged Securities Laws violations by Insmed Incorporated.

Investors who purchased shares of Insmed Incorporated (NASDAQ:INSM) have certain options and for certain investors are short and strict deadlines running. Deadline: September 13, 2016. NASDAQ:INSM investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.

The plaintiff claims that between March 18, 2013 and June 8, 2016 defendants issued allegedly false and misleading statements to investors and/or failed to disclose that the data on which Insmed’s European marketing authorization application for Arikayce, Insmed’s lead product candidate, relied was not likely to support approval by the European Medicines Agency (“EMA”) for the treatment of nontuberculous mycobacteria (“NTM”) lung disease, that Arikayce’s approval by the EMA for the treatment of NTM lung disease and subsequent commercialization in Europe were thus less likely and/or imminent than Insmed had led investors to believe, and that as a result, defendants’ statements about Insmed’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.. When the true details entered the market, the lawsuit claims that investors suffered damages.

Those who purchased shares of Insmed Incorporated (NASDAQ:INSM) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
[email protected]

Posted by ShareholdersFoundation on Tuesday August 16 2016, 12:15 AM EST. All trademarks acknowledged. Filed under Uncategorized. Comments and Trackbacks closed. Follow responses: RSS 2.0